Mayo Clinic has made important contributions to the treatment of IBD over the years, including pioneering the ileal pouch anal anastomosis surgery and laparoscopic surgery for ulcerative colitis. A Mayo Clinic researcher discovered that genetic differences significantly affected the way patients metabolized a widely used IBD drug, azathioprine and 6-mercaptopurine. Mayo Clinic researchers conducted the first clinical study of Asacol and have shown that nicotine is an effective therapy for ulcerative colitis.
Mayo Clinic's inflammatory bowel disease (IBD) serum and tissue biobank involves all Mayo Clinic campuses. Research into serologic and genetic markers may lead to individualized diagnosis and treatment.
Researchers in the Enteric Neuroscience Program (ENSP) on each of the Mayo Clinic campuses investigate the biology of the neuromuscular system of the gastrointestinal tract. They are conducting numerous clinical trials related to IBD and other conditions.
See a list of publications on inflammatory bowel disease by Mayo Clinic doctors on PubMed, a service of the National Library of Medicine.